drugset
drugset / Trial / NCT05107128

A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)

NCT05107128 ↗

Phase 2 Completed 189 enrolled Supernus Pharmaceuticals, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance and functioning in participants with HD.

Timeline

Start
2022-01-26
Primary completion
2024-09-04
Completion
2024-10-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Dalzanemdor Small molecule 0.9 mg Oral

Indications

Huntington disease